Gritstone bio

Gritstone bio Reports First Quarter 2024 Financial Results and Provides Corporate Updates

Retrieved on: 
星期四, 五月 9, 2024
PFS, FDA, SLATE, Administration, Research, HLA, Death, CRC, Doctor of Philosophy, National Cancer Institute, Vaccine, Development, IND, Melinda French Gates, NCI, AACR, Food, ESCMID, Roche, Messenger, HIV, Therapy, CEPI, Neoplasm, Infection, Gritstone bio, DNA, GMP, Clinical trial, Progression-free survival, Human services, Immunotherapy, Spark Therapeutics, MD, Disease, Patient, Acquisition, VAF, PD, COVID-19, Pharmaceutical industry

-- Gritstone to host conference call today at 4:30pm ET --

Key Points: 
  • In April 2024, Gritstone appointed Stephen Webster to its Board of Directors.
  • Mr. Webster was the Chief Financial Officer of Spark Therapeutics from July 2014 until its acquisition by Roche for $4.3 billion in December 2019.
  • Gritstone expects to share mature PFS data and additional long-term ctDNA data in the third quarter of 2024.
  • In April 2024, Gritstone presented a poster highlighting the durability and potential broad utility of its samRNA COVID-19 vaccine at ESCMID Global 2024.

Gritstone bio to Report First Quarter 2024 Financial Results and Provide Corporate Updates on May 9, 2024

Retrieved on: 
星期四, 五月 2, 2024
Vaccine, Gritstone bio

EMERYVILLE, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced it will report financial results for the first quarter 2024 and provide corporate updates after market close on Thursday, May 9, 2024. The announcement will be followed by a conference call and audio webcast, which will begin at 4:30pm ET.

Key Points: 
  • EMERYVILLE, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced it will report financial results for the first quarter 2024 and provide corporate updates after market close on Thursday, May 9, 2024.
  • The announcement will be followed by a conference call and audio webcast, which will begin at 4:30pm ET.
  • While not required, it is recommended you join five minutes prior to the event's start.
  • An archived replay will be accessible at https://ir.gritstonebio.com/investors/events for 30 days following the event.

Nature Medicine Publishes Interim Results from Gritstone bio’s Phase 1/2 Study of “Off-the-Shelf” Neoantigen Vaccine Platform (SLATE)

Retrieved on: 
星期一, 四月 15, 2024
SLATE, Mutation, Safety, HLA, Trial of the century, National Cancer Institute, Vaccine, Gritstone bio, Human, Antigen presentation, BRAF, Oncogene, Patient, TP53, NCI, CTNNB1, Pharmaceutical industry

EMERYVILLE, Calif., April 15, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, announced today that a paper detailing the development of its “off-the-shelf” neoantigen platform, SLATE, recently published in Nature Medicine. The paper, “A shared neoantigen vaccine combined with immune checkpoint blockade for advanced metastatic solid tumors: phase 1 trial interim results,” describes a novel immunodominance hierarchy of tumor neoantigens (including KRAS) that Gritstone discovered in Phase 1 translational studies and leveraged to develop SLATE-KRAS, a “pure” KRAS-directed candidate that demonstrated superior immunogenicity to the initial version in a subsequent Phase 2 study and is currently being evaluated in a novel cell therapy-vaccine combination study run by Steven A. Rosenberg of the National Cancer Institute (NCT06253520).

Key Points: 
  • "Our team’s innovative work to develop, optimize and validate SLATE positions Gritstone with two promising platforms to execute against our neoantigen-directed approach to oncology.
  • Neoantigens were identified using Gritstone bio’s proprietary neoantigen prediction platform, EDGETM, and selected based on shared mutation and matched HLA frequencies in patient populations with solid tumors.
  • These data led to the development of SLATE-KRAS, a vaccine focused on KRAS-derived neoantigens that subsequently was evaluated in the Phase 2 portion of the clinical study.
  • Initial Phase 2 data suggesting an increased vaccine induced T cell response were presented in September 2022 ( press release ).

Gritstone bio Presents Improvements to EDGE™ Platform at AACR 2024

Retrieved on: 
星期一, 四月 8, 2024
AP, Infection, HIV, Nature Biotechnology, Epitope, Cancer, SARS-CoV-2, Gritstone bio, HLA, AACR, Immunity, EDGE, Poster, Vaccine

EMERYVILLE, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today presented an update on its T cell epitope discovery platform, EDGE, at the 2024 American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA. The presentation details improvements Gritstone has made in prediction of peptide presentation by HLA Class I, associated with CD8+ T cells, since the publication of the initial results in 2018 (Nature Biotechnology). It also reviews how Gritstone has expanded EDGE’s application to predict peptide presentation by HLA Class II.

Key Points: 
  • The presentation details improvements Gritstone has made in prediction of peptide presentation by HLA Class I, associated with CD8+ T cells, since the publication of the initial results in 2018 ( Nature Biotechnology ).
  • It also reviews how Gritstone has expanded EDGE’s application to predict peptide presentation by HLA Class II.
  • “Identifying which of the hundreds of tumor mutations are most likely to serve as neoantigens, key targets of tumor-specific T cells, is critical to the development of effective neoantigen-directed vaccines,” said Andrew Allen, M.D., Ph.D., Co-founder, President, and Chief Executive Officer of Gritstone bio.
  • The improvements we are making to EDGE, leveraging advances in protein large language models and in-house immunopeptidomics, have positioned EDGE as a leading HLA/peptide predictive platform in the neoantigen cancer vaccine field.

Gritstone bio to Participate in Upcoming Investor and Scientific Conferences

Retrieved on: 
星期一, 四月 8, 2024
Vaccine, Gritstone bio, Clinical trial

EMERYVILLE, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced that management will be participating in the following investor and scientific conferences.

Key Points: 
  • EMERYVILLE, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced that management will be participating in the following investor and scientific conferences.
  • Select events (marked by *) will be webcasted live and webcast details will be available on the ‘Events’ page of Gritstone bio’s website: https://ir.gritstonebio.com/investors/events .
  • Archived replays will be accessible for 30 days following each event.
  • Presentation Title: Clinical Trial Results with a Personalised Neoantigen Vaccine in a Cold Tumour—Can We Bring the Heat?

Gritstone bio Announces Pricing of $32.5 Million Underwritten Public Offering

Retrieved on: 
星期二, 四月 2, 2024
Vanderbilt Avenue, TD Securities, Exercise, Form, Telephone, Sale, Attention, Gritstone bio, Form S-3, Vaccine, Equity capital markets, Evercore, Security (finance)

EMERYVILLE, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced the pricing of an approximately $32.5 million underwritten public offering of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) and accompanying common warrants to purchase common stock (or pre-funded warrants to purchase common stock in lieu thereof), before deducting underwriting discounts and commissions and offering expenses.

Key Points: 
  • EMERYVILLE, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced the pricing of an approximately $32.5 million underwritten public offering of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) and accompanying common warrants to purchase common stock (or pre-funded warrants to purchase common stock in lieu thereof), before deducting underwriting discounts and commissions and offering expenses.
  • The accompanying common warrants will be immediately exercisable for shares of common stock or pre-funded warrants in lieu thereof, and will expire on the twelve-month anniversary of the date of issuance.
  • All of the shares of common stock, accompanying common warrants and pre-funded warrants are being offered by Gritstone bio.
  • The securities are being offered by Gritstone bio pursuant to a registration statement on Form S-3 (File No.

Gritstone bio Announces Proposed Public Offering

Retrieved on: 
星期一, 四月 1, 2024
Vanderbilt Avenue, TD Securities, Form, Telephone, Sale, Attention, Gritstone bio, Form S-3, Vaccine, Equity capital markets, Evercore, Security (finance)

All of the shares of common stock, pre-funded warrants and accompanying common warrants are being offered by Gritstone bio.

Key Points: 
  • All of the shares of common stock, pre-funded warrants and accompanying common warrants are being offered by Gritstone bio.
  • The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
  • TD Cowen and Evercore ISI are acting as the joint book-running managers for the proposed offering.
  • The securities are being offered by Gritstone bio pursuant to a registration statement on Form S-3 (File No.

Gritstone bio Announces Positive Preliminary Progression-free Survival and Long-term Circulating Tumor DNA (ctDNA) Data from Phase 2 Portion of Ongoing Phase 2/3 Study of its Personalized Cancer Vaccine, GRANITE, in Front-line Metastatic Microsatellite St

Retrieved on: 
星期一, 四月 1, 2024
Lung cancer, Survival, Immunotherapy, Disease, Colorectal cancer, Progression-free survival, Medicine, Patient, Common, DNA, Aes, Cancer, Death, Doctor of Philosophy, Gritstone bio, MD, Kinetics, Induction chemotherapy, MSS, Circulating tumor DNA, VAF, Melanoma, PFS, Vaccine, Data, UCLA, Liver disease, Neoplasm, Pharmaceutical industry

EMERYVILLE, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced positive preliminary data from the ongoing, signal seeking Phase 2 portion of the Phase 2/3 study evaluating GRANITE, its personalized neoantigen cancer vaccine, in front-line metastatic microsatellite stable colorectal cancer (MSS-CRC). The randomized, controlled, open-label study is designed to quantify the clinical benefit of maintenance therapy with GRANITE (GRT-C901/GRT-R902) in combination with immune checkpoint blockade in addition to fluoropyrimidine/bevacizumab versus fluoropyrimidine/bevacizumab alone. Overall progression free survival (PFS) data show an early trend in benefit for GRANITE patients (HR=0.82, [95% CI, 0.34-1.67]; 62% censored) and extended PFS benefit in high-risk patients (HR=0.52 [95% CI, 0.15-1.38]; 44% censored), in whom progression occurs faster. Circulating tumor DNA (ctDNA) analysis over several months of treatment shows the expected relationship with disease progression and favors GRANITE, while short-term ctDNA response analysis (molecular response as defined per protocol) did not demonstrate a difference between study arms. Gritstone bio successfully manufactured GRANITE product candidate for every eligible patient (i.e., 100% vaccine manufacturing success rate).

Key Points: 
  • Gritstone bio successfully manufactured GRANITE product candidate for every eligible patient (i.e., 100% vaccine manufacturing success rate).
  • “Today's preliminary Phase 2 results are highly encouraging and represent the first randomized trial evidence, albeit early, that a personalized neoantigen-directed vaccine can potentially drive efficacy in a metastatic ‘cold’ tumor.
  • Fortunately, long-term analysis demonstrates the expected correlation of ctDNA with clinical benefit and favors GRANITE patients.
  • This analysis was performed on 44 patients who received study treatment (control and GRANITE arms) and have available baseline ctDNA data.

Serum Detect Launches with Novel T-Cell Analysis Approach for Cancer Early Detection at AACR

Retrieved on: 
星期四, 三月 28, 2024
Diagnosis, Lung cancer, Algorithm, University of Pennsylvania, Associate, Foundation Medicine, Biomedical Research, University, Research, DNA, Mortality, Cancer, Doctor of Philosophy, Gritstone bio, Serum, AACR, Neoplasm, TCR, Liquid biopsy, Blood, Antigen, Medical imaging

NEWTON, Mass., March 28, 2024 /PRNewswire/ -- Serum Detect , a cancer diagnostics company, is debuting a novel and promising approach for cancer early detection at the upcoming American Association for Cancer Research (AACR) conference.

Key Points: 
  • NEWTON, Mass., March 28, 2024 /PRNewswire/ -- Serum Detect , a cancer diagnostics company, is debuting a novel and promising approach for cancer early detection at the upcoming American Association for Cancer Research (AACR) conference.
  • The company is developing diagnostic tests, using standard liquid biopsy samples, that complement and enhance existing screening techniques for early detection of cancer.
  • "Detecting cancer early, before it has spread throughout the body, remains the primary way to achieve cancer cures.
  • Liquid biopsy, or the assessment of cancer through standard blood draws, is an important potential tool for cancer early detection.

Gritstone bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates

Retrieved on: 
星期二, 三月 5, 2024
Human services, Research, Gritstone bio, NCI, Messenger, Immunotherapy, FDA, Food, SLATE, GMP, National Cancer Institute, Vaccine, Administration, Autumn, COVID-19, Collaboration, Patient, Clinical trial, Infection, IND, Development, Workforce, HIV, Pharmaceutical industry

EMERYVILLE, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today reported financial results for the fourth quarter and full year ended December 31, 2023 and provided recent corporate and clinical updates.

Key Points: 
  • Positive signal in this metastatic context would likely unlock enormous opportunity in both adjuvant and metastatic solid tumors.
  • Gritstone met its enrollment target of 100 patients randomized in August 2023.
  • Cash, cash equivalents, marketable securities and restricted cash were $86.9 million as of December 31, 2023, compared to $185.2 million as of December 31, 2022.
  • Research and development expenses were $127.2 million for the year ended December 31, 2023 compared to $111.4 million for the year ended December 31, 2022.